Anthera Pharmaceuticals recently announced it has completed the enrolment of patients for its CHABLIS-SC1 Phase 3 study evaluating blisibimod as a lupus treatment. The company expects to have final data from the trial by the end of 2016. “Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” said in…
An international team led by researchers at the University of Bergen in Norway and the Weizmann Institute of Science in Israel recently published in the journal Immunity their finding that mutations in a gene known as autoimmune regulator (AIRE) are linked to different autoimmune phenotypes.
An international team of researchers recently published in the journal Nature Materials new findings on the activation of the body’s immune response in autoimmune disorders like systemic lupus erythematosus (SLE) and psoriasis. The study is entitled “Liquid-crystalline ordering of antimicrobial peptide–DNA complexes controls TLR9…
During the recent European League Against Rheumatism Annual Congress (EULAR 2015) that took place June 11-13 in Rome, Italy, new clinical recommendations for patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) who are trying to conceive or are currently pregnant were presented by the league. These new recommendations…
A study led by researchers at Ludwig Maximilians University Munich in Germany revealed a promising new biomarker linked to the lifespan control of important antibody-producing cells and relevant for autoimmune diseases like systemic lupus erythematosus (SLE). The study was recently published in the journal Nature Communications…
Systemic lupus erythematosus (SLE) treatments try to efficiently manage the disease while being safe and carrying a low rate of adverse events. Different strategies are currently used to control disease activity and prevent organ damage. To further understand if SLE is being adequately treated, a team of researchers lead by Dr. Christine Peschken looked at disease…
A new study recently published in the journal Nature Immunology revealed important insights into the generation of key cells of the immune system – dendritic cells. The study is entitled “Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common…
PharmaPoint, an industry leader in pharmacy management services, has published a report focused on lupus and its related therapeutic market, entitled “Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update.” Systemic lupus erythematosus (SLE) is an autoimmune disease in which the…
Lupus is a chronic disease for which there is currently no cure, with patients suffering with a lot of misconceptions and misunderstandings. Along with physicians, patients are the best people to discuss the disease, as is the case with Ellarea Maria Cole Stansbury, the author of the recently published book “…
Raanana, Israel based XTL Biopharmaceuticals Ltd. (XTL) has announced that following evaluation of market opportunity for its pipeline products its decision to focus efforts and expenditures exclusively on two core assets: hCDR1 for treatment of SLE/lupus and rHuEPO for “no-option” multiple myeloma patients. XTL, whose shares are traded on the…